Cargando…

Advances in Corticosteroid Therapy for Ocular Inflammation: Loteprednol Etabonate

Topical corticosteroids are effective in reducing anterior segment inflammation but are associated with adverse drug reactions (ADRs) including elevation of intraocular pressure (IOP) and cataract formation. Retrometabolic drug design has advanced the development of new corticosteroids with improved...

Descripción completa

Detalles Bibliográficos
Autores principales:	Comstock, Timothy L., DeCory, Heleen H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3321285/ https://www.ncbi.nlm.nih.gov/pubmed/22536546 http://dx.doi.org/10.1155/2012/789623

Ejemplares similares

Impact of the Topical Ophthalmic Corticosteroid Loteprednol Etabonate on Intraocular Pressure
por: Sheppard, John D., et al.
Publicado: (2016)

Development of a non-settling gel formulation of 0.5% loteprednol etabonate for anti-inflammatory use as an ophthalmic drop
por: Coffey, Martin J, et al.
Publicado: (2013)

An update on the surgical management of pterygium and the role of loteprednol etabonate ointment
por: Sheppard, John D, et al.
Publicado: (2014)

Loteprednol Etabonate for the Treatment of Dry Eye Disease
por: Beckman, Kenneth, et al.
Publicado: (2020)

Loteprednol etabonate (submicron) ophthalmic gel 0.38% dosed three times daily following cataract surgery: integrated analysis of two Phase III clinical studies
por: Fong, Raymond, et al.
Publicado: (2019)

Safety and efficacy of loteprednol etabonate ophthalmic ointment 0.5% for the treatment of inflammation and pain following cataract surgery
por: Comstock, Timothy L, et al.
Publicado: (2011)

Ocular Pharmacokinetics of a Novel Loteprednol Etabonate 0.4% Ophthalmic Formulation
por: Schopf, Lisa, et al.
Publicado: (2014)

Review of Loteprednol Etabonate 0.5%/Tobramycin 0.3% in the Treatment of Blepharokeratoconjunctivitis
por: Mah, Francis S., et al.
Publicado: (2021)

Rheological Properties, Dissolution Kinetics, and Ocular Pharmacokinetics of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%
por: Cavet, Megan E., et al.
Publicado: (2019)

Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Inflammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Binary Polymeric Surfactant Mixtures for the Development of Novel Loteprednol Etabonate Nanomicellar Eyedrops
por: Tampucci, Silvia, et al.
Publicado: (2023)

Loteprednol etabonate ophthalmic suspension 0.5 %: efficacy and safety for postoperative anti-inflammatory use
por: Amon, Michael, et al.
Publicado: (2012)

Practical Guidance for the Use of Loteprednol Etabonate Ophthalmic Suspension 0.25% in the Management of Dry Eye Disease
por: Venkateswaran, Nandini, et al.
Publicado: (2022)

Loteprednol etabonate: Dematiaceous fungal colonisation by Bipolaris species in the left eye: case report
Publicado: (2020)

Comparison between Betamethasone, Fluorometholone and Loteprednol Etabonate on intraocular pressure in patients after keratorefractive surgery
por: Shokoohi-Rad, Saeed, et al.
Publicado: (2017)

A retrospective analysis of the use of loteprednol etabonate ophthalmic suspension 0.5% following canaloplasty
por: Khaimi, Mahmoud A
Publicado: (2018)

Loteprednol etabonate gel 0.5% for postoperative pain and inflammation after cataract surgery: results of a multicenter trial
por: Fong, Raymond, et al.
Publicado: (2012)

Correction to: Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38%: A Review in Post-Operative Infammation and Pain Following Ocular Surgery
por: Kang, Connie, et al.
Publicado: (2020)

Real-World Use of Loteprednol Etabonate 0.5%/Tobramycin 0.3% Ophthalmic Suspension for the Treatment of Ocular Surface Inflammatory Conditions
por: Deom, James E, et al.
Publicado: (2022)

Cytarabine-Induced Corneal Toxicity: Clinical Features and Relief of Symptoms with Loteprednol Etabonate 0.5% in Two Patients
por: Özcan, Gökçen, et al.
Publicado: (2021)

Dose Uniformity of Loteprednol Etabonate (Submicron) Ophthalmic Gel 0.38% Compared with Prednisolone Acetate Ophthalmic Suspension 1%
por: Marlowe, Zora T., et al.
Publicado: (2021)

Dose uniformity of loteprednol etabonate ophthalmic gel (0.5%) compared with branded and generic prednisolone acetate ophthalmic suspension (1%)
por: Marlowe, Zora T, et al.
Publicado: (2014)

In Vitro Time-Kill of Common Ocular Pathogens with Besifloxacin Alone and in Combination with Benzalkonium Chloride
por: Blondeau, Joseph, et al.
Publicado: (2021)

A retrospective analysis of the postoperative use of loteprednol etabonate gel 0.5% following laser-assisted in situ keratomileusis or photorefractive keratectomy surgery
por: Salinger, Clifford L, et al.
Publicado: (2015)

Real world use of loteprednol etabonate ophthalmic gel 0.5% in cases representative of comorbid pathologies responding to minimally invasive glaucoma surgery
por: Sheppard, JD, et al.
Publicado: (2019)

Antibiotic resistance among bacterial conjunctival pathogens collected in the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) surveillance study
por: Asbell, Penny A., et al.
Publicado: (2018)

Critical appraisal of loteprednol ointment, gel, and suspension in the treatment of postoperative inflammation and pain following ocular and corneal transplant surgery
por: Pirouzian, Amir, et al.
Publicado: (2014)

Besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis patients with Pseudomonas aeruginosa infections
por: Silverstein, Bruce E, et al.
Publicado: (2012)

Antibiotic Resistance Among Pediatric-Sourced Ocular Pathogens: 8-Year Findings From the Antibiotic Resistance Monitoring in Ocular Microorganisms (ARMOR) Surveillance Study
por: Alter, Sherman J., et al.
Publicado: (2019)

Efficacy of olopatadine hydrochloride 0.1%, emedastine difumarate 0.05%, and loteprednol etabonate 0.5% for Chinese children with seasonal allergic conjunctivitis: a randomized vehicle‐controlled study
por: Liu, Rui‐fen, et al.
Publicado: (2016)

Trends in Antibiotic Resistance Among Ocular Microorganisms in the United States From 2009 to 2018
por: Asbell, Penny A., et al.
Publicado: (2020)

Remogliflozin Etabonate in the Treatment of Type 2 Diabetes: Design, Development, and Place in Therapy
por: Mohan, Viswanathan, et al.
Publicado: (2020)

Integrated analysis of three bacterial conjunctivitis trials of besifloxacin ophthalmic suspension, 0.6%: microbiological eradication outcomes
por: Morris, Timothy W, et al.
Publicado: (2011)

Efficacy and safety of a 3-month loteprednol etabonate 0.5% gel taper for routine prophylaxis after photorefractive keratectomy compared to a 3-month prednisolone acetate 1% and fluorometholone 0.1% taper
por: Mifflin, Mark D, et al.
Publicado: (2017)

An Evaluation of Staphylococci from Ocular Surface Infections Treated Empirically with Topical Besifloxacin: Antibiotic Resistance, Molecular Characteristics, and Clinical Outcomes
por: Schechter, Barry A., et al.
Publicado: (2019)

The Role of Nitric Oxide in the Intraocular Pressure Lowering Efficacy of Latanoprostene Bunod: Review of Nonclinical Studies
por: Cavet, Megan E., et al.
Publicado: (2018)

Antibacterial efficacy of prophylactic besifloxacin 0.6% and moxifloxacin 0.5% in patients undergoing cataract surgery
por: Bucci, Frank A, et al.
Publicado: (2015)

Exploring glycosuria as a mechanism for weight and fat mass reduction. A pilot study with remogliflozin etabonate and sergliflozin etabonate in healthy obese subjects
por: Napolitano, Antonella, et al.
Publicado: (2013)

Use of loteprednol for routine prophylaxis after photorefractive keratectomy
por: Mifflin, Mark D, et al.
Publicado: (2012)

Comparison of Loteprednol with Fluorometholone after Myopic Photorefractive Keratectomy
por: Karimian, Farid, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_bmj0c6g6la9madbimstb8hirh3